Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib in Advanced Sarcoma
NCT03670069Phase 1Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itacitinib in leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS) and 3 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Difference in the percentage of cells which are immune inhibitory (CD11B+, CD163+) macrophages. Started Sep 2019; status: terminated.
02
Drugs
itacitinib
03
Conditions
leiomyosarcoma (LMS)undifferentiated pleomorphic sarcoma (UPS)synovial sarcoma (SS)myxoid liposarcoma (MLPS)myxoid/round cell liposarcoma (MRCLS)
Beyond the preview
Go deeper on NCT03670069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03670069.